
In many ways, Leo Pharma is headed into unknown territory after the firm secured fast-track status for its drug candidate delgocitinib from the US Food and Drug Administration, FDA.
The company could become the first to send a drug to market in the US specifically targeting chronic hand eczema, for which delgocitinib has received a special status.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app